Oligonucleotide Therapeutics and Delivery Conference

Circulating MicroRNAs Likely as Effective as A1C for Predicting Type 2 Diabetes in Youth

Type 2 diabetes in young people ages 10 to19 has more than doubled in the past 20 years, yet it remains difficult for physicians to predict who will be diagnosed and who will improve with treatment.Readmore

Taking RNAi from interesting science to impactful new treatments

The researchers had done foundational work to understand how RNAi, which is a naturally occurring process, works to silence genes through the degradation of messenger RNA.Readmore

Welcome to a brave new world of therapeutics

The field of RNA therapeutics has expanded incredibly over the last 30 years, and mRNA-based COVID-19 vaccines are just the start.Readmore

A new RNA editing tool could enhance cancer treatment

The new study found that an RNA-targeting CRISPR platform could tune immune cell metabolism without permanent genetic changes, potentially unveiling a relatively low-risk way to upgrade existing cell therapies for cancer.Readmore

New RNA Therapeutics Core Facility to Drive Cutting-Edge Research

RNA-based technologies, such as the COVID-19 vaccine, are quickly advancing and hold promise to treat diseases ranging from inherited metabolic conditions and autoimmune disorders to cancer and cardiovascular disease.Readmore

New CRISPR Center Brings Hope for Rare and Deadly Genetic Diseases

CRISPR collaboration combines expertise from three UC schools to scale treatment for diseases that industry has largely passed by – until now.Readmore

Discovery could lead to new RNA therapeutics for many cancers

Australian scientists have made a major discovery that could underpin the next generation of RNA-based therapeutics, and lead to more potent and longer-lasting RNA-based drugs with an even wider array of potential uses.Readmore

Advancing AOCs to transform the delivery of RNA therapeutics

Recent clinical advances and product approvals have demonstrated significant progress in the development of first-generation RNA therapeutics, for instance with antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs).Readmore

Qalsody is an antisense oligonucleotide that targets SOD1 mRNA

FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosisReadmore

Fostering the Next Generation of Antisense Oligonucleotide Therapies

Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works bReadmore

Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies

SAN DIEGO,Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agreement with GSK plc (LSE/NYSE: GSK) to advance the discovery and development of ElReadmore

Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products

Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology IncReadmore

Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual diseaseReadmore

GenScript Expands Peptide and Oligonucleotide Production Facility in China

GenScript’s new life-science building in China; facilities offer fast-turnaround, high-purity oligonucleotide and peptide synthesis service for R&D and preclinical applicationsReadmore

Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

Chinook Therapeutics partners with Ionis Pharmaceuticals to advance precision medicine for rare kidney disease. Leveraging Chinook’s expertise in nephrology and Ionis’ RNA-targeted therapeutics, the collaboration aims to develop an antisense oligonuclReadmore

UMass Chan scientists deliver siRNA therapy to lung

Delivery technology successfully blocks SARS-CoV-2 infection in mice; adaptable for multiple diseasesReadmore

Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger

The RNA-edited therapy developer prepares to combine with Frequency Therapeutics, focusing initially on liver and CNS disordersReadmore

UMass Chan scientists deliver siRNA therapy to lung

Scientists at UMass Chan Medical School have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease. Readmore

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into Research and option Agreement in the Field of CNS Diseases

Discovery and development of innovative therapeutics for the treatment of neurological diseases, today announced the signature of a multi-target research and option agreement. Within the collaboration, the companies will work together to generate novel ASReadmore

Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that address important unmet medical needs, today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to Readmore

Aptamer Group partner with BaseCure Therapeutics to develop new targeted gene therapies

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies.Readmore

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).Readmore

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleoReadmore